- Home
- GNPX vs PMCB Comparison
GNPX vs PMCB Comparison
Compare GNPX & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- PMCB
- Stock Information
- Founded
- GNPX 2009
- PMCB 1996
- Country
- GNPX United States
- PMCB United States
- Employees
- GNPX N/A
- PMCB N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNPX Health Care
- PMCB Health Care
- Exchange
- GNPX Nasdaq
- PMCB Nasdaq
- Market Cap
- GNPX 6.6M
- PMCB 7.6M
- IPO Year
- GNPX 2018
- PMCB N/A
- Fundamental
- Price
- GNPX $0.23
- PMCB $1.05
- Analyst Decision
- GNPX
- PMCB
- Analyst Count
- GNPX 0
- PMCB 0
- Target Price
- GNPX N/A
- PMCB N/A
- AVG Volume (30 Days)
- GNPX 3.6M
- PMCB 8.5K
- Earning Date
- GNPX 08-08-2025
- PMCB 08-12-2025
- Dividend Yield
- GNPX N/A
- PMCB N/A
- EPS Growth
- GNPX N/A
- PMCB N/A
- EPS
- GNPX N/A
- PMCB 1.29
- Revenue
- GNPX N/A
- PMCB N/A
- Revenue This Year
- GNPX N/A
- PMCB N/A
- Revenue Next Year
- GNPX N/A
- PMCB N/A
- P/E Ratio
- GNPX N/A
- PMCB $0.82
- Revenue Growth
- GNPX N/A
- PMCB N/A
- 52 Week Low
- GNPX $0.20
- PMCB $1.00
- 52 Week High
- GNPX $3.97
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- GNPX 40.22
- PMCB 47.26
- Support Level
- GNPX $0.22
- PMCB $1.00
- Resistance Level
- GNPX $0.32
- PMCB $1.07
- Average True Range (ATR)
- GNPX 0.03
- PMCB 0.05
- MACD
- GNPX -0.01
- PMCB 0.01
- Stochastic Oscillator
- GNPX 22.07
- PMCB 39.78
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.